Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Heine, GH; Eller, K; Stadler, JT; Rogacev, KS; Marsche, G, ;RITERM, study, group;RITERM, study, group.
Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations.
Pharmacol Ther. 2020; 207:107459
Doi: 10.1016/j.pharmthera.2019.107459
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Marsche Gunther
- Co-Autor*innen der Med Uni Graz
- Eller Kathrin
- Stadler Julia
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Chronic kidney disease (CKD), which affects >10% of the population worldwide, is associated with a dramatically increased rate of cardiovascular disease (CVD). More people with CKD will die from CVD than develop end-stage renal disease with dialysis-dependency. However, the contribution of classical atherosclerotic cardiovascular risk factors is less evident than in the general population. Particularly, the relationship between dyslipidemia and CVD morbidity and mortality in CKD patients is not as evident as in the general population. While LDL cholesterol-lowering drugs such as statins significantly reduce the rate of cardiovascular events in the general population, their role in patients with end-stage renal disease has been questioned. This could be caused by a shift from atherosclerotic to non-atherosclerotic CVD in patients with advanced CKD, which cannot be effectively prevented by lipid-lowering drugs. In addition, many lines of evidence suggest that impaired renal function directly affects the metabolism, composition and functionality of lipoproteins, which may affect their responsiveness to pharmacological interventions. In this review, we highlight the challenges for the therapeutic application of lipid-lowering treatment strategies in CKD and discuss why treatment strategies used in the general population cannot be applied uncritically to CKD patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Cardiovascular Diseases - blood, drug therapy, epidemiology, physiopathology
- Cholesterol, LDL - blood
- Dyslipidemias - blood, drug therapy, epidemiology, physiopathology
- Humans - administration & dosage
- Hypolipidemic Agents - therapeutic use
- Lipid Metabolism - drug effects
- Renal Insufficiency, Chronic - blood, drug therapy, epidemiology, physiopathology